Kestra Medical Technologies, Inc.

Kestra Medical Technologies manufactures the ASSURE® Wearable Cardioverter Defibrillator (WCD) system, a non-invasive, wearable medical device designed to protect patients at elevated risk of sudden cardiac arrest (SCA). The system targets heart failure patients and those with reduced left ventricular ejection fraction (LVEF ≤35%) awaiting clinical improvement or subsequent therapeutic intervention. The ASSURE system comprises three integrated components: the wearable defibrillator device with autonomous arrhythmia detection and highly effective defibrillation therapy; the Kestra CareStation™, a cloud-based remote patient data management platform enabling clinician oversight and patient data integration; and the ASSURE patient mobile application to enhance compliance and patient engagement during recovery. The company positions itself at the intersection of digital health, smart wearables, mobile connectivity, and cardiac protection. Kestra's clinical evidence includes the ACE-PAS (ASSURE® WCD Clinical Evaluation Post-Approval Study), described as the largest prospective real-world study of wearable defibrillators to date, demonstrating safety, performance, and real-world effectiveness. The device is FDA-cleared and represents a modern approach to temporary cardiac risk management in ambulatory and home settings. Kestra serves cardiologists, hospitals, and heart failure programs across the United States and maintains international presence.